UsAgainstAlzheimer’s Statement on Discontinuation of AstraZeneca and Eli Lilly Alzheimer’s Drug

UsAgainstAlzheimer’s President Drew Holzapfel today issued the following statement regarding the discontinuation of clinical trial testing of the Alzheimer’s drug lanabecestat by AstraZeneca and Eli Lilly and Company:

“This is another hard day for the Alzheimer’s community, but we say to each patient and caregiver: We will not stop until we have cured this disease.

“We also applaud trial participants and their care partners. Thank you for your courage and investment. You have contributed to an important body of work that will help inform the development of the eventual cure. AstraZeneca and Eli Lilly should be commended for their continued commitment and leadership in helping the more than 50 million people touched by Alzheimer’s globally.

“To government, investors, entrepreneurs, innovators and industry: it’s time to double down. Further investments are urgently needed so we can overcome this disease.”

 

###